• Relay Therapeutics, Inc. recently reported first-quarter 2026 results showing revenue of US$3.00 million and a net loss of US$73.29 million, while outlining plans to advance its lead PI3Ka inhibitor zovegalisib with Pfizer’s atirmociclib into Phase 3 for frontline PI3Ka‑mutated, HR+/HER2- metastatic breast cancer.
• What stands out is that in heavily pre-treated patients, the zovegalisib triplet regimen showed an objective response rate approaching current first-line doublet therapies, which could be meaningful for a large precision oncology population if future trials support these early findings.
• We’ll now examine how Relay Therapeutics’ move toward a Phase 3 breast cancer program for zovegalisib shapes its broader investment narrative.

The latest GPUs need a type of rare earth metal called Neodymium and there are only 33 companies in the world exploring or producing it. Find the list for free.

What Is Relay Therapeutics' Investment Narrative?

For Relay Therapeutics, the investment case really comes down to whether you believe zovegalisib can anchor a meaningful PI3Ka‑mutated breast cancer franchise before the company runs short of financial flexibility. The new Phase 3 ambitions in frontline disease, backed by triplet data that approaches first‑line doublet response rates in much sicker patients, sharpen the near term catalyst map: regulatory feedback on trial design, continued ReDiscover updates, and the ongoing Breakthrough Therapy program in second line. At the same time, Q1 revenue of just US$3.00 million, a net loss of US$73.29 million, and the proposal to increase authorized shares to 450 million keep funding risk firmly in view, with potential dilution now a more immediate consideration. The recent data raise the stakes on both sides of that equation.

However, the plan to increase authorized shares is something investors really need to understand. Our expertly prepared valuation report on Relay Therapeutics implies its share price may be too high.

Exploring Other Perspectives

The Simply Wall St Community’s single fair value view at US$21.00 sits against a market still digesting Relay’s deep losses and ambitious Phase 3 plans. You are seeing one number, but a thesis that now leans heavily on trial execution risk and potential dilution, which is exactly where investor opinions could start to diverge sharply.

Explore another fair value estimate on Relay Therapeutics - why the stock might be worth as much as 65% more than the current price!

Decide For Yourself

Disagree with this assessment? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Relay Therapeutics research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Relay Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Relay Therapeutics' overall financial health at a glance.

Seeking Other Investments?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• We've uncovered the 12 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Invest in the nuclear renaissance through our list of 91 elite nuclear energy infrastructure plays powering the global AI revolution.
• Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.